The $100 Billion Cancer Industry Missed This One Thing

What if the best cancer care for you can't be a mass produced product? What if the medicine, the dose and even the delivery route has to be custom built for your specific cancer targets, not because it's fancy, but because it's necessary. This is the world of N of 1 Precision Oncology. Very different than the current standard oncology, which is pretty much run by a national comprehensive cancer network guidelines that all the oncologists are using. And it's these changes that make a world of difference. We're going to look in this episode how groups like St. Jude's Hospital is working in the area of precision and how we for the last two and a half decades have been in the area of precision oncology and why it's really important for all patients to have access. I'm Dr. Dino Prado. For the last two decades we've helped patients who failed the top hospitals across the country and we've helped map out their cancer biology with deep information, tumor microenvironment, immunity. And today I want to educate you on a simple but powerful idea that a lot of people are missing. The very best care for unique cancer often can't come off the shelf and it's not a one size fits all. It must be custom designed. And that's what no one is all about. So to show why, let's start with a model many people already admire and understand. It's called the St. Jude's Children Research Hospital. That does amazing work for children and I'm going to bring in these insights directly to adult precision oncology, which is what we do. The St. Jude model is so important when mass market doesn't exist for children with pediatric conditions that are unique cancers. St. Jude focuses on catastrophic pediatric diseases and runs unique operating models that are precision designed. The majority of the funding that they get from donors is to really help these families and to help these kids with cancer with travel, housing and care. If a family has insurance, say Jude may try to bill it, but often much of the care may not get covered. So why? Because the technology they're using isn't standard of care. This lets the team pursue what the child needs. So let me tell you something that's important. Pharmaceutical companies aren't interested in drugs that are only going to treat a few kids. So they're not going to develop. There's no money in it. Insurance companies don't like to cover things that they don't know are going to produce revenue for them and hospitals aren't equipped to do that. So this is called research and development. And so St. Jude's has built this ecosystem with kids with exotic cancers where big pharma isn't going to commercially make the drug, do the testing, then develop the drug in house and then deliver it. Well, that sounds pretty interesting, doesn't it? Because these children need these kind of pediatric drugs so that they can live. This is important, this is what St. Jude's has done and invested heavily in this ecosystem for these exotic cancers. Because the one size fits all model and pipeline wasn't working, they had to build this. So this is the key takeaway I want you to get because we're going to move this right into adult precision oncology here in a minute. When a disease is rare or uniquely configured, you must design it outside the box. You need unique testing, custom drug design and delivery. One of the interesting things to understand is that cancer today is heterogeneous, meaning two people with the same cancers, type and stage, have totally different cancers because we have thousands of markers. Deep learning on the DNA and next generation sequencing, the RNA transcriptomics, the immune spatial biology. And so when you bring this all together, here's the reveal. Every cancer patient needs n of one and a unique ecosystem. It's not really just for the St. Jude's kids. And the reason this is important is because it doesn't exist for adults. So in the last two and a half decades I've worked with my team to build that. So I'm going to share with you what we have found and why this is so important. So this precision approach, when you do the detailed markers, everybody needs a custom build and you need an ecosystem that's unique. Deep mapping, meaning the care is built on you, not on the population that has your type and stage of cancer, but your unique molecular biology. This is what makes all the difference. This is where I think we're going to get closer to the cure of cancer and longer term remissions. So let's start with this. First you have the DNA which is the next generation sequence. This identifies actionable mutations. Now the problem here is, let's say we're running 500 genes or plus you're only going to have a few commercial drugs that are available. So you have to go custom build the medicines for those other actionable DNA mutations which currently don't have approved FDA drugs. Sound unique? Sounds similar to what St. Jude's doing. Absolutely. Now let's move to RNA. So RNA transcriptomics, these are the drivers. It's telling us where the cancer is going, where the resistant pathways are. So we can see that looking at 8001000 plus markers. So now we've got tons of markers and we don't have actionable targets for most of those. So we have to go build those custom for the patient. And then we have one of the most important parts of cancer, which is immune spatial biology, where we can see the environment around the cancer cell. I've always used this analogy. If you have a cancer cell and you put a drone up in the sky, you can see all the gangs blocking the police of your immun getting to the tumor. And so we can unblock it by seeing what those spatial neighborhoods look like. And there's not approved drugs for every one of those. So we have to go custom build those. We have to understand what's blocking the body's immune system from getting the treatment it needs. The stromal barriers, the lack of oxygen around the tumors. This is so important. So this multi layer targeted mapping actually explains why the drug might work or fail. The custom drug design is the key part of the playbook. So when we go to make a medication, we're looking at on label. These are drugs already approved for this type of cancer. We're also looking at off label or repurposed drugs. These have become more popular over the years. But the problem is there are only a few repurposed drugs people are talking about instead. When you do deep mapping, you can build that library extensively to look at all of the drugs that have mechanisms and targets for your specific markers. So it goes beyond the methylene blues or the ivermectin or the menbendazole. You get the idea. It goes way beyond that because the repurposing of the drug is custom designed for the patient based on their targets. Then we discover not just that, but phytotherapeutics. What are these? All the plants that have to be made in intravenous formulations in nanoparticle delivery to actually impact the cancer cell biology. Humans and cg and quercetin and I can go on. There's so many of them. And these have to be custom built to work in your pathways. So now when you start looking at this, you have 1 plus 1 equaling 11, I like to say, or a lot more because the combinations are so powerful. Then you have this other category, fourth category, even the most important, called cellular biologics, where you build the immune system to fight the cancer. No matter. Phytotherapeutics you do, how much inflammation you decrease, how many antioxidants and treatments you use. The immune system has to do the work. And you sometimes often have to build the immune system from your natural killer cells and dendritic cells, change the terrain and reestablish immunity. And this has to be done for each patient in cellular biologics. So we've been doing that for 18 years in our international facility. And cellular biologics gives you a huge advantage to making cold tumors hot and helping patients respond. So you can see all this custom build is very similar to what we saw with St. Jude's because it has each individual. Sometimes the best path is not standard care, it's targeted care. It's microdosed for you, designed with multi agents for you, combinations for you, reducing the toxicity and changing the landscape of the cancer. Because if we give a chemotherapy iv, it may not get to the cancer because the cancer already may be walled off from that treatment. It doesn't matter if it's a natural agent or a conventional agent, it just won't get there. So we have to get to the tumor using image guided surgery. We use a catheter the size of a hair that's so small, we go in and go right to the tumor, deliver it, and then seal the blood cel supply so the tumor dies and we get this immune system reaction throughout the body. This is powerful because now we're getting an immune centric response. Think about what I've just mentioned to you, how targeted this is. This isn't being done everywhere. This is a special ecosystem. You need special testing, you need special pharmacy to make the medicines, combine them. You need special surgical suites to deliver the agents or infusions. And you do this all with the environment of healing and immune centric. So this is important. And once you've done this, now you're moving in the right direction. And you want to monitor care. So just going beyond imaging and tumor markers, you want to look at circulating tumor cells, CT free DNA methylation. So now you get leading indicators, and these leading indicators are telling you, hey, you're moving in the right direction. So now you have the power of precision oncology. You're not waiting months and months for responses. You can see it in real time. This is the big advantage. So we're not going to wait for pharma to go develop all these drugs and all these targets. This will take many, many decades. Patients can't wait that long. They need that kind of work now, and the sooner the better. That's what we call precision oncology. See, instead of looking for what works for the averages, the general population, population, the double blind placebo clinical trials, which is for the averages. It's almost like socialized medicine. What everybody gets for this type and stage of cancer. We work to precision using deep learning, AI, deep mapping, custom drug design and custom delivery. And this is why we get the power of care. You can see that St. Jude has done great work in helping these children with exotic and complex cancers. But we're doing this for everybody, even at a higher level, because we're custom designing it and delivering it for the patient. So this makes a big difference. If you look at an example, I'm going to use a name like Elena. 61 year old, recurrent ovarian cancer. She had standard chemo. It didn't work. Her deep mapping revealed the right targets, got the immune system in place, monitor her, got her the right phytotherapeutics, reestablished her cytokines, her immune modulating capacity. Now she was able to fight the cancer and was able to take a disease that was not responding well and bring it into remission. Let's go through this for breast cancer, prostate cancer, colon cancer, endometrium. I can keep going because this is what we've done for 25 years, hitting the drivers at the right doses for the patients. So this, this is the precision oncology ecosystem. And one of the best ways for people to see this, because you may not be familiar with precision oncology, is to look at the St. Jude's model and see how they've done that in pediatric cancer. Now imagine a more integrative precision network done for all adults and all cancer types. That's the work we've been doing for two and a half decades. This, in our clinical experience, gives better quality of life and better outcomes. I'm not just saying that. In 2024 we published a paper that showed that we had 35 times better responses in late stage CANC cancer than conventional care, 35 times and 43 times better quality of life. This is huge. It's a huge advantage and that is in 24. And our data now is even better and improving because the data continues to improve. In fact, stay tuned. We're going to be publishing on that coming up soon. So why isn't this care automatic for everybody? Well, just like St. Jude's had to build an independent ecosystem to serve these kids, we had to build an independent ecosystem for n of one care that requires custom labs, custom compounding pharmacies, and go beyond the standard of care delivery so that we can help our patients. Insurance doesn't cover these. The PBMs can't make the money on these. This is why this care is slow to getting out there. It's usually driven by the cancer industrial complex, which I've done in other videos. You're welcome to watch this. It's reimbursement based, what the hospitals are doing. But here we need to talk about what is unique and custom for each patient. What I call the key to unlocking cancer is these key combinations that are immune focused for each patient. So you don't have to struggle, you don't have to try to find a treatment that works and bounce around from one place to another. What you really need is n of one custom treatment and what I've seen in my clinical experience and you need to advocate for yourself. You need to ask, am I getting the right DNA and RNA testing, immune spatial biology, Is the treatment being custom built for me? What are my unique drivers? You need to ask, are you using the right on label, off label and repurposed drugs? Are you using the right phytotherapeutics that are delivered in the correct manner? Are you getting the right immunotherapies? See, this is all the right question because if you can match those to your targets, the better your targets are matched, the better better your response is going to be. In my clinical experience, it's totally common sense in what we've seen clinically work. I hope this was helpful and may the Lord bless you on your journey to healing.